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Summary A total of 535 chemotherapy naive, hospitalised patients (263 male/272 female) scheduled to
receive cisplatin (50-120mg m-2)-containing regimens participated in a randomised, double-blind, parallel
group study to evaluate the efficacy and safety of three intravenous dose schedules of ondansetron in the
prophylaxis of acute nausea and emesis. One hundred and eighty two patients received a loading dose of 8 mg
of ondansetron followed by a 24 h infusion of 1 mg h-I (group 1); 180 and 173 patients received single doses
of 32mg (group II) and 8 mg (group III) respectively, followed by a 24 h placebo infusion. Complete and
major control ( <2 emetic episodes) of acute emesis was achieved in 74% ofpatients in group I, 78% in group
II and 74% in group III. Seventy seven per cent of the patients in group I, and 75% of patients in groups II
and III respectively experienced no or mild nausea during the 24 h observation period. A retrospective
stratification of the efficacy data on the basis of patient gender showed the response rate in females to be
significant lower (43% vs 67%; <0.001). Ondansetron was well tolerated; mild headache was the most
commonly reported adverse event (11% of patients) with a similar incidence in the three groups ofpatients. In
conclusion, a single intravenous dose of 8 mg of ondansetron given prior to chemotherapy is as effective as a
32 mg daily dose given as either a single dose or a continuous infusion in the prophylaxis of acute
cisplatin-induced emesis.
A considerable advance was made in alleviating one of the
most distressing side effects of cytotoxic treatment when it
was demonstrated that high-dose metoclopramide considerably
improved the control of cisplatin-induced emesis (Gralla et
al., 1981). Since then, high-dose metoclopramide has been the
cornerstone of effective anti-emetic combinations (Kris et al.,
1987; Roila et al., 1989). However, it can induce extra-
pyramidal reactions especially in adolescents, and this re-
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mains a major drawback. A recent advance has been the
development of specifit 5-HT3 receptor antagonists which
prevent chemotherapy or, radiotherapy-induced emesis with-
out inducing extrapyramidal reactions (Clark et al., 1990).
The 5-HT3 receptor antagonist ondansetron (ZofranR) has
been shown to be superior to high-dose metoclopramide in
the control of acute cisplatin-induced emesis when given
intermittently as short infusions (0.15 mg kg-' x 3, 4-hourly)
(Pendergrass et al., 1990) or by a constant infusion (8 mg,
then 1 mgh-' 24h-') (de Mulder et al., 1990; Marty et al.,
1990). The pattern of emesis observed in the latter two
studies indicated that for patients who received meto-
clopramide and then experienced emesis, this occurred most
frequently in the first 6-12 h following cisplatin. This pattern
was not evident with ondansetron suggesting good control in
this early period. The patterns of emesis observed with
ondansetron and metoclopramide were similar for the
remainder of the 24 h period. The urinary excretion of
5-hydroxyindole acetic acid (5HIAA), a metabolite of 5-HT,
also has been shown to increase in the 4-6 h period after
cisplatin paralleling the onset of emesis (Cubeddu et al.,
1990). These observations suggested that shorter treatment
regimens of ondansetron may be as effective as the con-
tinuous infusion or multiple dose schedules employed in the
initial comparative studies. Moreover, results from studies
with high-dose metoclopramide (Roila et al., 1991) and other
5-HT3 receptor antagonists, granisetron and tropisetron
(Soukop, 1990; Sorbe et al., 1990), have shown that single
doses of these agents, given prior to chemotherapy, are
effective in controlling acute symptoms.
This study was therefore designed to determine whether
the recommended daily dose of 32 mg of ondansetron (de
Mulder 1990; Marty et al., 1990), when given as a single
intravenous dose prior to chemotherapy, is as safe and
effective as the established 24 h continuous infusion in the
prevention of acute cisplatin-induced emesis. It further investi-
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gated the contribution made by the continuous infusion of
1 mg h-' to efficacy by the inclusion of a third dosing arm, a
single 8 mg dose. If affective, single prophylactic doses would
be advantageous in terms of convenience and ease of
administration benefiting both patients and nursing staff; the
8 mg dose would have the additional advantage of reducing
cost of treatment.
Patients and methods
Patients
Male or female patients, aged at least 18 years, who were
scheduled to receive their first course of chemotherapy with
cisplatin at a dose of 50-120 mg m-2 given over a period of
up to 4 h, either alone or in combination with other cytotoxic
drugs, were eligible for the study. Patients were excluded if
they experienced nausea or vomiting and/or received anti-
emetic therapy in the 24 h period prior to the start of the
treatment, had a serious concurrent illness other than cancer
or another aetiology for emesis, and concurrently used corti-
costeroids (except for physiological supplementation) or
benzodiazepines (unless given for night sedation).
A complete history and physical examination were carried
out prior to treatment. Blood samples were taken for full
blood cell count, electrolytes, liver and renal function prior
to starting the study, and repeated after 24 h and 1-4 weeks
later. Informed consent was obtained from all the patients.
The study protocol was approved by local Hospital Ethics
Committees and the study was conducted according to the
principles of the Declaration of Helsinki.
Study design and treatment
The required number of patients was calculated under the
assumption that complete and major anti-emetic control
(0-2 emetic episodes) would be achieved in 75% of the
patients with the continuous infusion schedule. Using two-
sided tests at an overall 5% significance level and a power of
0.8, 170 patients (of whom 150 could be expected to be
evaluable) would be required in each group to detect a
difference of at least 15% between the continuous infusion
regimen and either of the two single dose regimens. The trial
design allowed for an interim analysis when approximately
50 patients in each treatment group were recruited. If the
analysis provided clear evidence of a treatment difference,
then the study could be terminated or recruitment could be
halted into the inferior study arm.
Eligible patients were entered sequentially and randomly
allocated to one of the three ondansetron schedules. The
randomisation sequence was computer-generated and
balanced the treatment in blocks of nine patients. The
ondansetron and placebo infusions were prepared by a
dedicated nurse, physician or pharmacist not involved with
the care or the evaluation of the patient to ensure blindness.
The loading dose of either 8 mg (group I and III) or 32 mg
(group II) of ondansetron was diluted to a 100 ml of saline,
and administered over 15 min starting 30 min prior to the
initiation of the cisplatin infusion. This was followed by a
24 h continuous infusion, either with 1 mg h-' of ondanset-
ron (group I) or the same volume of saline solution (group II
and III). The cisplatin infusion was set up 15 min after the
start of the continuous infusion and run over 1-4 h.
Assessment ofefficacy and side effects
All patients were monitored in hospital for the 24 h after the
start in the cisplatin infusion. Nausea was assessed by the
patient before treatment, and at 8 and 24 h after treatment,
using a four-point graded scale (none, mild - did not
interfere with normal daily life, moderate - interfered with
daily life, severe - bedridden due to nausea). The timing and
number of emetic episodes were recorded and cross-checked
with the patient. A single emetic episode was defined as a
single vomit or retch (vomit not productive of liquid), or any
number of continuous vomits or retches. Each episodes was
separated by the absence of symptoms for at least 1 min. The
overall response criteria for emesis were: complete response
(CR): 0 emetic episodes, major response (MR): 1-2, minor
response (MR): 3-5, and failure (F): > 5 emetic episodes.
Patients who experienced three or more emetic episodes and
were rescued with additional anti-emetic medication were
considered to be treatment failures. Any adverse medical
events that occurred during the study (or the follow-up
period of 1-4 weeks) were recorded and the severity and
relationship to ondansetron assessed.
Statistical analysis
All analyses were performed on the total population (inten-
tion to treat analysis) providing efficacy data were available,
as well as the evaluable population (with satisfactory proto-
col compliance). The proportions of patients showing a
complete or a complete plus major response were compared
between treatments using a two-sided Mantel-Haenszel chi-
square test stratified by centre. The time to first emetic
episode was compared for all pairs of treatment using Wil-
coxon rank sum analysis. A separate analysis was also car-
ried out after stratification by country, using the Van Elteren
method for combining Wilcoxon statistics over strata (Van
Elteren, 1960). The grades of nausea for the 8 and 24 h after
chemotherapy were analysed using the stratified, extended
Mantel-Haenszel method. Subset analysis for the difference
in gender, cisplatin dose and concurrent chemotherapy was
carried out using the chi-square test of 2 x 2-, 2 x 3- and
2 x 4-tables.
Results
The interim analysis of data on the first 149 patients on an
intention to treat basis indicated that complete or major
control of emesis was achieved in 36/46 (78%) patients with
the continuous infusion schedule (group I), 42/50 (84%)
patients with the 32 mg single dose regimen (group II) and in
40/53 (76%) patients with the 8 mg single dose regimen
(group III). As there appeared to be no differences between
the groups, a statistical analysis was not carried out and the
study was progressed to completion.
Between September 1989, and June 1990, 535 patients with
pathologically confirmed cancer were enrolled in the study.
Demographic characteristics of the 535 patients entered into
the trial are shown in Table I. Details of the doses of
cisplatin (median 72 mg m-2) and type of concurrent chemo-
therapy administered to patients in each treatment group are
given in Table II. There were no significant differences in age,
gender, average alcohol intake, primary tumour site, doses of
cisplatin administered or administration times and con-
comitant chemotherapy among the three treatment groups.
There were 42 patients who did not fully comply with the
protocol. Of these, 12 received concurrent anti-emetics, seven
were not chemotherapy naive, 18 received an incorrect cis-
platin dose schedule, four had severe concurrent illness and
one was withdrawn due to an adverse event which was
unrelated to ondansetron treatment. The analyses of the
efficacy results of the total and the evaluable populations did
not reveal any differences in the overall conclusions. Therefore,
the efficacy results presented here are for the 'intention to treat
population' since this more closely reflects clinical practice.
Acute nausea and emesis
Pre-treatment nausea was absent in 94% of the patients, 5%
of the patients had mild nausea. After 8 h of study treatment
88% (I), 87% (II), and 85% (III) of the patients had none or
mild nausea. The percentage of patients experiencing none or
mild nausea after 24h were 77% in group I and 75% in
groups II and III (P >0.5). The results are shown in Figure 1.194 C. SEYNAEVE et al.
Table I Patient demography
Number ofpatients (%)
8mg+Jmgh-' 32mg 8mg Total
Patients randomised 182 180 173 535
Sex
Male 82 (45) 95 (53) 86 (50) 263 (49)
Female 100 (55) 85 (47) 87 (50) 272 (51)
Age (years)
19-29 10 (5) 12 (7) 5 (3) 27 (5)
30-65 136 (75) 117 (65) 120 (69) 373 (70)
>65 36 (20) 51 (28) 48 (28) 135 (25)
Median 57.5 60 60 59
Range 19.84 19.77 25.82 19.84
Primary tumour site
Head and neck 31 (17) 30 (17) 27 (16) 88 (16)
Lung 30 (16) 41 (23) 39 (23) 110 (21)
Gastrointestinal 15 (8) 10 (6) 9 (5) 34 (6)
Genitourinary 28 (15) 22 (12) 25 (15) 75 (14)
Gynaecological 67 (38) 66 (37) 65 (38) 200 (37)
Bone/soft tissue 3 (2) 3 (2) 4 (2) 10 (2)
Miscellaneous 11 (4) 13 (3) 11 (1) 35 (4)
Alcohol intake
None of <7/week 143 (79) 40 (78) 132 (76) 415 (78)
1-4u/day 25 (14) 25 (14) 27 (16) 77 (14)
>4 u/day 14 (8) 14 (8)) 13 (8) 41(8)
1 unit of alcohol = one measure of spirit, one glass of wine or 250 ml of
beer.
Results for the control of acute emesis are shown in Figure
2. Complete and major responses were achieved in 74%
(Group I), 78% (Group II) and 74% (Group III) of patients.
In the pairwise treatment comparisons, there were no statisti-
cally significant differences between the three dose regimens.
The pattern of emesis, expressed as the total number of
episodes occurring at hourly intervals over 24 h was similar
in the three groups of patients (Figure 3).
Fifty two per cent of patients in group I, 53% in group II
and 51% in group III had no emesis and reported none or
mild nausea over the 24 h period.
Influence ofcisplatin dose and concomitant chemotherapy
A retrospective stratification of efficacy data (emesis data) on
the basis of the doses of cisplatin administered and concur-
rent treatment with other cytotoxic agents revealed that there
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Figure I Control of acute nausea with the continuous infusion
(n = 182), 32 mg single dose (n = 17) schedules: nausea graded as
none E; mild L1; moderate M; severe = at 8 and 24 h
after cisplatin administration.
were no statistically significant differences between the treat-
ment groups for these prognostic factors. Stratification of the
pooled data is shown in Table III. Overall, complete control
of emesis was achieved in a significantly greater proportion
of patients (157/242, 65%) who received cisplatin at doses
<70mgM-2 compared with 137 of 293 (48%) patients who
received higher doses of cisplatin (> 70 mg m2; P <0.001).
Of the 107 patients who received cisplatin at doses
100mgm-2, complete control was achieved at 16 or 34
(47%), 21 of 46 (46%). and II of 27 (41%) of patients in
Groups I, II, and III respectively. The concurrent use of
other moderately emetogenic agents also significantly affected
the degree of control of emesis; complete control was
achieved in 114 of 167 (68%) patients who received cisplatin
alone, compared with 84 of 190 (44%) patients who received
other emetogenic cytotoxic agents concurrently (P <0.001).
Influence ofpatient gender
A retrospective stratification of the efficacy data on the basis
of patient gender revealed that there were no statistically
significant differences between the treatment groups for this
factor. However, stratification of the pooled efficacy data as
shown in Tables III and IV indicated that overall, complete
control of emesis was achieved in a significantly higher pro-
portion of male patients (67% vs 43%, P <0.001). The
observed difference was not influenced by the doses of cis-
Table II Concurrent chemotherapy and cisplatin dose
Number of patients (%)
8mg+ I mgh-' 32mg 8mg
Patients randomised
Concurrent chemotherapy
None
Cyclo/ifosfamide
Epi/doxorubicin
Cyclphosph/epi/
doxorubicin
Eto/teniposide
5-Fluorouracil
Miscellaneous4
Cisplatin dose
< 50 mg m-2
50-69.9mgm-2
70-99.9 mgm-2
> OOmgm-2
Median dose (mgm-2)
Range
Mean administration time (h)
182
58
32
17
13
18
16
28
11 (6)
79 (43)
58 (32)
34 (19)
70
30- 125
2.63
180 173 535
57
37
14
8
21
17
26
6 (3)
66 (37)
62 (34)
46 (26)
63
36
11
11
19
14
19
10 (6)
70 (40)
66 (38)
27 (16)
178
105
42
32
58
47
73
27 (5)
215 (40)
186 (35)
107 (20)
76 71 72
31 - 124 37- 153 30- 153
2.33 2.43 2.46
'Miscellaneous: bleomycin, vincristine, vinblastine, vindesine, methotrexate,
mitoxanthrone, mitomycin, dacarbazine.
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Figure 2 Control of acute emesis with the continuous infusion
(n = 182), 32 mg single dose (n = 180) and 8 mg single dose
(n = 173) schedules: complete control X; major control E;
minor control M; failure =.
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Figure 3 Episodes of emesis during the 24 h after cisplatin
administration with the continuous infusion (0 0), 32 mg single
dose (-) and 8 mg single dose (....) schedules.
Table III Proportions of patients with complete responses stratified
on the basis of patient gender, cisplatin dose and concomitant
chemotherapy
Prognostic factor Total number ofpatients (%)'
Patient
Male 177/263 (67%)
Female 117/272 (43%)
Cisplatin dose
<70mg-2 157/242 (65%)
70-99 ng m-2 90/186 (48%)
> 100mgm-2 47/107 (44%)
Concomitant chemotherapy
None 114/167 (68%)
Mildly emetogenic 96/178 (54%)
Moderately emetogenic 84/190 (44%)
aPooled data; the differences were consistent within each treatment
group. Concomitant chemotherapy: moderately emetogenic: cyclo-
phosphamide, ifosfamide, epi/doxorubicin, dacarbazine; mildly
emetogenic: 5-fluorouracil, mitoxanthrone, mitomycin, bleomycin,
etoposide, vinblastin, vincristine.
platin or concurrent cytotoxic agents administered to the
patients.
Adverse events
All three dosage schedules were well tolerated; in particular,
the 32 mg single dose was not associated with an increase in
the incidence ofadverse events. The most commonly reported
events considered by the investigator to be possibly, probably
or almost certainly related to ondansetron are listed in Table
Table IV Proportions of male and female patients with complete
responses, stratified on the basis of cisplatin dose and concomitant
chemotherapy
Number of patients (%)
Male Female
Cisplatin dose
<70 mg m-2 89/114 (78) 68/128 (53)
70-99 mg m-2 53/84 (63) 37/102 (36)
> 100 mg m-2 35/63 (56) 13/44 (27)
Concomitant chemotherapy
None 84/109 (77) 30/58 (52)
Mildly emetogenic 71/123 (58) 25/55 (45)
Moderately emetogenic 22/31 (71) 62/159 (39)
Concomitant chemotherapy: moderately emetogenic: cyclophos-
phamide, ifosfamide, epi/doxorubicin, dacarbazine; mildly emetogenic:
5-fluorouracil, mitoxantrone, mitomycin, bleomycin, etoposide,
vinblastin, vincristine.
V. Headache was the most commonly reported adverse event
(11% of patients). None of these patients were withdrawn
from the study and the symptoms resolved spontaneously or
were treated with mild analgesics. Two major adverse events
were considered to be possibly related to ondansetron treat-
ment: one case of severe constipation and one case of pseudo-
membranous colitis, which resolved spontaneously. Transient
changes in ALT/AST which were considered to be related to
ondansetron, occurred in four patients of group I, in seven
patients of group II and in two patients of group III. All
changes resolved at follow-up, and none were associated with
any clinical signs or symptoms.
Discussion
Several studies have shown ondansetron to be a safe and
efficacious anti-emetic in the prevention of cisplatin-induced
emesis. Pharmacokinetic modelling suggested that ondanset-
ron given as an 8 mg intravenous loading dose followed by
I mg h-' for 24 h would give consistent plasma levels of
30ngml '. These levels were considered to be optimal for
blocking 5HT3 receptors and maximising anti-emetic efficacy.
Two comparative trials which investigated the efficacy of this
selected dosing schedule (de Mulder et al., 1990; Marty et al.,
1990) showed ondansetron to be superior to high-dose
metoclopramide in the prophylaxis of acute cisplatin-induced
emesis. This trial has investigated whether single prophylactic
doses of ondansetron are as effective as the constant infusion
schedule and the contribution ofthe 24 h continuous infusion
to overall efficacy. Single dose prophylaxis would have
obvious benefits to patients and hospital staff alike, and in
addition, lower effective doses would reduce the cost of
treatment.
The most striking observation in this study is the similarity
in anti-emetic control achieved with the three treatment
schedules, either for complete and/or major response (ap-
proximately 75% of patients) as well as for the control of
emesis and nausea considered together (approximately 52%
of patients). These results are consistent with two other
comparative trials that investigated the efficacy of the con-
Table V Adverse events
Number of patients (%)
Adverse event 8mg + 1 mgh-' 32mg 8mg Total
(n = 182) (n = 180) (n = 173) (n = 535)
Headache 16 (9) 25 (14) 20 (12) 61 (11)
Diarrhoea 3 (2) 5 (3) 5 (3) 13 (2.5)
Constipation 3 (2) 3 (2) - 6 (1)
Flushing 2 (1) 2 (1) 4 (0.8)
Xerostomia 1 (0.5) 3 (2) - 4 (0.8)
Laboratory changes 4 (2) 7 (4) 2 (1) 13 (2.5)
Miscellaneous 11 (6) 14 (8) 10 (6) 35 (7)
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tinuous infusion regimen of ondansetron (de Mulder et al.,
1990; Marty et al., 1990), and a recent trial where complete
control of emesis was reported in 58% of patients with a
single intravenous dose of 32 mg and in 57% with the con-
tinuous infusion schedule (Marty & d'Allens, 1990).
The patterns ofemesis over the 24 h period in patients who
experienced emesis provide further evidence that the three
dose schedules are equally efficacious. The half-life of
elimination of ondansetron is approximately 3.5 h in healthy
volunteers (Blackwell & Harding, 1989) and young patients
(Lazarus et al., 1990) but may be up to 7 h in elderly patients
(Priestman et al., 1990). Following a single bolus dose of
8 mg of ondansetron, plasma levels fall to below 5 ng ml-' at
12h, compared to consistent levels of 30-50ng ml-' with
the continuous infusion schedule used in this study (Colthup
& Palmer, 1989; Seynaeve et al., 1990). The similar degree of
anti-emetic control and pattern of emesis experienced by
patients in the three treatment groups indicates that the
constant plasma levels afforded by the continuous infusion
regimen confer no additional benefit during the acute phase
ofemesis. This emphasises that the period up to 12 h follow-
ing the cisplatin infusion may be the critical period for acute
anti-emetic control. During this period, elevations in urinary
levels of 5-HIAA, a urinary metabolite of 5HT, have been
observed (Cubeddu et al., 1990). The plasma levels afforded
by the 8 mg single dose are probably adequate for antagonis-
ing 5HT-mediated emesis at 5HT3 receptors, providing pro-
tection in the majority ofpatients. Continuous antagonism at
5HT3 receptors in the 24 h following cisplatin may not be
necessary for conferring any additional benefit, hence the
similar efficacies observed with the 8 mg single dose and
constant infusion schedules.
Several prognostic factors (Tonato et al., 1991) such as
previous exposure to chemotherapy, patient age, gender,
chronic alcohol use, and dose of cisplatin administered are
known to affect the control of chemotherapy-induced nausea
and vomiting. This large parallel group study was designed
to include chemotherapy-naive patients only and all the
important prognostic factors were well balanced within the
three groups. The comparable efficacy observed with the
8 mg single dose, in particular, cannot therefore be attributed
to a chance selection of patients who were likely to have a
more favourable response into this treatment group.
Some interesting points emerged from the retrospective
stratifications of response based on gender and the concur-
rent use of cytotoxic agents. It is known that emesis in
women is more difficult to control than in men (Tonato et
al., 1991), but it is not clear whether this is due to an
underlying mechanism(s) or the more frequent use of
moderately emetogenic agents such as cyclosphosphamide or
doxorubicin with cisplatin in women. In this study, the
degree of control of emesis (complete response) was
significantly lower in female patients. This difference was
consistently observed in further retrospective stratifications to
determine the effect of cisplatin dose or concurrent
chemotherapy on treatment outcome in men and women.
Our results suggest that although the use of concurrent
cytotoxics affect treatment outcome in women, they are not
an influencing factor on their own and that other factor(s)
therefore may be involved. Humoral factors (Carl et al.,
1989) are unlikely to explain the observed differences between
men and women. Whole blood and plasma 5-HT levels are
higher in healthy women than men but no data are available
on the fluctuation in levels of the neurotransmitter in patients
of different gender receiving chemotherapy (Ortiz et al.,
1988). It is known that anticipatory nausea and vomiting in
chemotherapy-induced emesis are associated with a suscepti-
bility to motion sickness and anxiety in addition to other
characteristics (Morrow & Dobkin, 1988). It may also be
that these factors are particularly relevant to women in the
control of chemotherapy-induced emesis. Further attempts to
elicit the physiological mechanism should be encouraged.
Moreover, further studies should utilise prospective
stratifications based on patient gender and cisplatin doses
and include a pre-trial history about anxiety, motion sickness
and vomiting during pregnancy (Martin & Diaz-Rubio, 1990)
to determine the effect of these factors on treatment outcome
and to optimise the most suitable prophylactic anti-emetic
regimens for women.
In the population studied, the majority of patients (80%)
received cisplatin at doses < 100 mg m-2 and the continuous
infusion of 1 mg h-' or a higher single dose of 32 mg confer-
red no additional benefits over a single 8 mg dose. It is
known that the degree of emesis experienced by cisplatin-
treated patients is related to the dose of cisplatin
administered (Tonato et al., 1991) and complete control of
emesis was achieved in a significantly lower proportion of the
107 patients who received cisplatin at doses 100mgm-2.
Within this group of 107 patients (20% of patients) there
were no statistically differences in response rates between the
three treatment schedules. However, the power of the com-
parisons was lower than that carried out for the response
rates between treatment groups for patients who received
cisplatin at doses <70mgm2.
Although serotonin is a significant mediator of acute
emesis (Cubeddu et al., 1990), failure to completely protect
all patients indicates that other mechanism(s) may also be
involved. The addition of dexamethasone to ondansetron has
been shown to significantly improve anti-emetic control
(Roila et al., 1991). As the mechanism and site of action of
dexamethasone are not yet known, it is possible that dexa-
methasone contributes to overall efficacy by suppressing one
or more of these additional mechanism(s).
The adverse events considered to be related to ondansetron
were generally mild in nature, and the incidences were similar
between the treatment schedules. As previously observed,
headache was the most common event.
In conclusion, this study shows that a single intravenous
dose of 8 mg of ondansetron is as efficacious as a 32 mg daily
dose in the prophylaxis of acute cisplatin-induced emesis. In
the population studied, a continuous infusion of I mg/hour
for 24 h conferred no additional benefit in anti-emetic protec-
tion. The efficacy of single dose anti-emetic prophylaxis is
likely to improve patient and nursing staff acceptance of
ondansetron; moreover, it should allow out-patient treatment
where appropriate.
We wish to thank the nurses in the different centres who were
involved with the recording of data and Dr J. Verweij for advice in
preparation of the manuscript.
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